サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1566970

臨床免疫分析装置市場：タイプ別、用途別、エンドユーザー別：世界の機会分析と産業予測、2024～2033年

Clinical Immunoanalyzer Market By Type , By Application By End user : Global Opportunity Analysis and Industry Forecast, 2024-2033

出版日
ページ情報
英文 216 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.69円
臨床免疫分析装置市場：タイプ別、用途別、エンドユーザー別：世界の機会分析と産業予測、2024～2033年
出版日: 2024年07月10日
発行: Allied Market Research
ページ情報: 英文 216 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

臨床免疫分析装置市場は、2023年に47億米ドルと評価され、2024～2033年にかけてCAGR 5.5%で成長し、2033年には80億米ドルに達すると予測されています。

臨床免疫分析装置は、患者サンプル中の抗体、抗原、その他の免疫系成分などの様々な免疫学的マーカーの定量的・定性的分析を行うために、医療試験室で使用される診断機器です。臨床免疫分析装置は、正確で迅速な結果を提供することにより、臨床現場において疾患の診断、免疫反応のモニタリング、治療方針の決定に重要な役割を果たしています。これらの分析装置は試験結果を迅速に提供するため、タイムリーな診断と治療方針の決定に不可欠です。

臨床免疫分析装置の世界市場の成長は、がん、自己免疫疾患、感染症などの慢性疾患の憂慮すべき有病率の上昇と、早期かつ正確な診断の重視の高まりによって牽引されています。調査によると、世界人口の約20%が糖尿病や心血管疾患などの慢性疾患を患っており、定期的なモニタリングと診断が必要です。このため、関連バイオマーカーを効率的に検出できる臨床免疫分析装置の需要が高まっています。さらに、高齢者人口の急増が世界市場の主要な原動力となっています。これは、高齢者が様々な病気にかかりやすいという事実が、高度な診断ソリューションの必要性を高めているためです。世界保健機関（WHO）によると、2019年の60歳以上の高齢者数は10億人でした。この数は2030年までに14億人、2050年までに21億人に増加すると推定されています。高齢者人口の増加に伴い、慢性疾患の罹患率は大幅に上昇すると予想されます。さらに、健康や予防医療に対する意識の高まりが、より良い健康管理のための高度な診断ツールの使用を促進し、市場の成長を増大させています。メーカーは、試験室のワークフローを合理化し、人的ミスを減らし、スループットを向上させるために、免疫分析装置の自動化に注力しています。また、データの解釈を強化し、プロセスを自動化し、診断精度を向上させるために、免疫分析装置にAIとMLを統合しています。こうした動向は、先進的な診断機器の導入率向上に大きく寄与しています。しかし、高度な免疫分析装置の初期投資とメンテナンスコストが高く、定期的なメンテナンス、キャリブレーション、技術サポートが必要であることが、市場の成長を抑制しています。さらに、多くの国では国民のニーズを満たす適切な医療施設がなく、アクセスが限られていることが市場の主要阻害要因となっています。その一方で、アッセイ技術の改良が進み、バイオマーカーのより正確で信頼性の高い検出を可能にする高感度・高特異度化が進んでいるため、予測期間中に世界市場の拡大に有利な機会がもたらされると期待されています。さらに、新興国市場における医療インフラの開拓が、これらの地域における臨床免疫分析装置の採用を促進し、市場規模を拡大しています。

世界の臨床免疫分析装置産業は、タイプ、アプリケーション、エンドユーザー、地域に区分されます。タイプ別では、市場はELISA、CLIA、RIA、その他に分類されます。用途別では、臨床化学、内分泌、腫瘍、感染症診断、循環器、その他に分類されます。エンドユーザー別では、病院・クリニック、診断ラボ、研究機関、その他に細分化されます。地域別では、北米、欧州、アジア太平洋、ラテンアメリカ・中東・アフリカで分析されています。

主要調査結果

タイプ別では、ELISAセグメントが2024～2033年にかけて市場を独占すると予測されます。

用途別では、感染症診断が予測期間中に主要セグメントとして浮上すると予測されます。

病院・クリニックセグメントは、今後数年間、臨床免疫分析装置の主要エンドユーザーとして機能すると予測されています。

地域別では、臨床免疫分析装置市場は近い将来、北米全域で大きな成長を遂げる可能性が高いです。

本レポートのカスタマイズが可能です。

  • 規制ガイドライン
  • 顧客の関心に応じた追加企業プロファイル
  • 平均販売価格分析/価格帯分析
  • 企業プロファイルの拡大リスト
  • 償還シナリオ

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場情勢

  • 市場の定義と範囲
  • 主要調査結果
    • 主要投資機会
    • 主要成功戦略
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会

第4章 臨床免疫分析装置市場：タイプ別

  • 市場概要
  • ELISA
  • CLIA
  • RIA
  • その他

第5章 臨床免疫分析装置市場：用途別

  • 市場概要
  • 臨床化学
  • 内分泌学
  • 腫瘍学
  • 感染症診断
  • 循環器
  • その他

第6章 臨床免疫分析装置市場：エンドユーザー別

  • 市場概要
  • 病院とクリニック
  • 診断ラボ
  • 研究機関
  • その他

第7章 臨床免疫分析装置市場：地域別

  • 市場概要
  • 北米
    • 主要市場動向と機会
    • 米国の臨床免疫分析装置市場
    • カナダの臨床免疫分析装置市場
    • メキシコの臨床免疫分析装置市場
  • 欧州
    • 主要市場動向と機会
    • フランスの臨床免疫分析装置市場
    • ドイツの臨床免疫分析装置市場
    • イタリアの臨床免疫分析装置市場
    • スペインの臨床免疫分析装置市場
    • 英国の臨床免疫分析装置市場
    • その他の欧州の臨床免疫分析装置市場
  • アジア太平洋
    • 主要市場動向と機会
    • 中国の臨床免疫分析装置市場
    • 日本の臨床免疫分析装置市場
    • インドの臨床免疫分析装置市場
    • 韓国の臨床免疫分析装置市場
    • オーストラリアの臨床免疫分析装置市場
    • その他のアジア太平洋の臨床免疫分析装置市場
  • ラテンアメリカ・中東・アフリカ
    • 主要市場動向と機会
    • ブラジルの臨床免疫分析装置市場
    • 南アフリカの臨床免疫分析装置市場
    • サウジアラビアの臨床免疫分析装置市場
    • その他のラテンアメリカ・中東・アフリカの臨床免疫分析装置市場

第8章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10企業の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング（2023年）

第9章 企業プロファイル

  • Roche Diagnostics Corporation
  • Abbott
  • Siemens AG.
  • Beckman Coulter
  • Ortho-Clinical Diagnostics
  • Bio-Rad
  • BioMerieux
  • DiaSorin S.p.A.
  • Werfen Life
  • Thermo Fisher Scientific
目次
Product Code: A324391

The clinical immunoanalyzer market was valued at $4.7 billion in 2023, and is projected to reach $8.0 billion by 2033, growing at a CAGR of 5.5% from 2024 to 2033.

Clinical immunoanalyzer is a diagnostic instrument used in medical laboratories to perform quantitative and qualitative analyses of various immunological markers such as antibodies, antigens, and other immune system components in patient samples. By providing accurate and rapid results, clinical immunoanalyzers play a critical role in diagnosing diseases, monitoring immune responses, and guiding treatment decisions in clinical settings. These analyzers deliver quick turnaround times for test results, which is crucial for timely diagnosis and treatment decisions.

The growth of the global clinical immunoanalyzer market is driven by alarming rise in prevalence of chronic conditions such as cancer, autoimmune diseases, and infectious diseases and increase in emphasis on early and precise diagnosis. Studies have shown that approximately 20% of the global population suffers from chronic diseases such as diabetes and cardiovascular disorders, which require regular monitoring and diagnostics. This drives the demand for clinical immunoanalyzers capable of efficiently detecting relevant biomarkers. Furthermore, surge in geriatric population acts as the key driving force of the global market. This is attributed to the fact that aged individuals are highly susceptible to various diseases, which fosters the need for advanced diagnostic solutions. As per the World Health Organization, the number of people aged 60 years and older was 1 billion in 2019. This number is estimated to increase to 1.4 billion by 2030 and 2.1 billion by 2050. With increasing aged population, the incidence of chronic conditions is expected to rise significantly. Moreover, increase in awareness about health and preventive care promotes the use of advanced diagnostic tools for better health management, which augments the market growth. Manufacturers are focusing on automation of immunoanalyzers to streamline laboratory workflows, reduce human error, and increase throughput as well as integration of AI and ML into immunoanalyzers to enhance data interpretation, automate processes, and improve diagnostic accuracy. These trends are notably contributing to higher adoption rates of advanced diagnostic equipment. However, high initial investment and maintenance costs of advanced immunoanalyzers and need for regular maintenance, calibration, and technical support restrain the market growth. Moreover, lack of appropriate health facilities to meet population needs in most countries and limited access act as the key deterrent factors of the market. On the contrary, ongoing improvements in assay technologies are leading to higher sensitivity and specificity to enable more accurate and reliable detection of biomarker are expected to offer lucrative opportunities for expansion of the global market during the forecast period. Furthermore, development of healthcare infrastructure in emerging markets is driving the adoption of clinical immunoanalyzers in these regions, expanding market reach.

The global clinical immunoanalyzer industry is segmented into type, application, end user, and region. On the basis of type, the market is categorized into ELISA, CLIA, RIA, and others. Depending on application, it is categorized into clinical chemistry, endocrinology, oncology, infectious disease diagnostics, cardiology, and others. By end user, it is fragmented into hospitals & clinics, diagnostic laboratories, research institutes, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By type, the ELISA segment is expected to dominate the market from 2024 to 2033.

On the basis of application, infectious disease diagnostics is anticipated to emerge as the leading segment during the forecast period.

The hospitals & clinics segment is projected to serve as the major end user of clinical immunoanalyzers in the coming years.

Region wise, the clinical immunoanalyzer market is likely to experience significant growth across North America in the near future.

Competition Analysis

Competitive analysis and profiles of the major players in the global clinical immunoanalyzer market include Roche Diagnostics Corporation, Abbott, Siemens AG., Beckman Coulter, Ortho-Clinical Diagnostics, Bio-Rad, bioMerieux, DiaSorin S.p.A., Werfen Life, and Thermo Fisher Scientific. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and strengthen their foothold in the global market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Average Selling Price Analysis / Price Point Analysis
  • Expanded list for Company Profiles
  • Reimbursement Scenario

Key Market Segments

By Type

  • ELISA
  • CLIA
  • RIA
  • Others

By Application

  • Clinical Chemistry
  • Endocrinology
  • Oncology
  • Infectious Disease Diagnostics
  • Cardiology
  • Others

By End User

  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Research Institutes
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Key Market Players:

    • Roche Diagnostics Corporation
    • Abbott
    • Siemens AG.
    • Beckman Coulter
    • Ortho-Clinical Diagnostics
    • Bio-Rad
    • bioMerieux
    • DiaSorin S.p.A.
    • Werfen Life
    • Thermo Fisher Scientific Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: CLINICAL IMMUNOANALYZER MARKET, BY TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Type
  • 4.2. ELISA
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. CLIA
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. RIA
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country
  • 4.5. Others
    • 4.5.1. Key Market Trends, Growth Factors and Opportunities
    • 4.5.2. Market Size and Forecast, By Region
    • 4.5.3. Market Share Analysis, By Country

CHAPTER 5: CLINICAL IMMUNOANALYZER MARKET, BY APPLICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Application
  • 5.2. Clinical Chemistry
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Endocrinology
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Oncology
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country
  • 5.5. Infectious Disease Diagnostics
    • 5.5.1. Key Market Trends, Growth Factors and Opportunities
    • 5.5.2. Market Size and Forecast, By Region
    • 5.5.3. Market Share Analysis, By Country
  • 5.6. Cardiology
    • 5.6.1. Key Market Trends, Growth Factors and Opportunities
    • 5.6.2. Market Size and Forecast, By Region
    • 5.6.3. Market Share Analysis, By Country
  • 5.7. Others
    • 5.7.1. Key Market Trends, Growth Factors and Opportunities
    • 5.7.2. Market Size and Forecast, By Region
    • 5.7.3. Market Share Analysis, By Country

CHAPTER 6: CLINICAL IMMUNOANALYZER MARKET, BY END USER

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By End User
  • 6.2. Hospitals And Clinics
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Diagnostic Laboratories
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Research Institutes
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country
  • 6.5. Others
    • 6.5.1. Key Market Trends, Growth Factors and Opportunities
    • 6.5.2. Market Size and Forecast, By Region
    • 6.5.3. Market Share Analysis, By Country

CHAPTER 7: CLINICAL IMMUNOANALYZER MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Type
    • 7.2.3. Market Size and Forecast, By Application
    • 7.2.4. Market Size and Forecast, By End User
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Clinical Immunoanalyzer Market
      • 7.2.6.1. Market Size and Forecast, By Type
      • 7.2.6.2. Market Size and Forecast, By Application
      • 7.2.6.3. Market Size and Forecast, By End User
    • 7.2.7. Canada Clinical Immunoanalyzer Market
      • 7.2.7.1. Market Size and Forecast, By Type
      • 7.2.7.2. Market Size and Forecast, By Application
      • 7.2.7.3. Market Size and Forecast, By End User
    • 7.2.8. Mexico Clinical Immunoanalyzer Market
      • 7.2.8.1. Market Size and Forecast, By Type
      • 7.2.8.2. Market Size and Forecast, By Application
      • 7.2.8.3. Market Size and Forecast, By End User
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Type
    • 7.3.3. Market Size and Forecast, By Application
    • 7.3.4. Market Size and Forecast, By End User
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. France Clinical Immunoanalyzer Market
      • 7.3.6.1. Market Size and Forecast, By Type
      • 7.3.6.2. Market Size and Forecast, By Application
      • 7.3.6.3. Market Size and Forecast, By End User
    • 7.3.7. Germany Clinical Immunoanalyzer Market
      • 7.3.7.1. Market Size and Forecast, By Type
      • 7.3.7.2. Market Size and Forecast, By Application
      • 7.3.7.3. Market Size and Forecast, By End User
    • 7.3.8. Italy Clinical Immunoanalyzer Market
      • 7.3.8.1. Market Size and Forecast, By Type
      • 7.3.8.2. Market Size and Forecast, By Application
      • 7.3.8.3. Market Size and Forecast, By End User
    • 7.3.9. Spain Clinical Immunoanalyzer Market
      • 7.3.9.1. Market Size and Forecast, By Type
      • 7.3.9.2. Market Size and Forecast, By Application
      • 7.3.9.3. Market Size and Forecast, By End User
    • 7.3.10. UK Clinical Immunoanalyzer Market
      • 7.3.10.1. Market Size and Forecast, By Type
      • 7.3.10.2. Market Size and Forecast, By Application
      • 7.3.10.3. Market Size and Forecast, By End User
    • 7.3.11. Rest of Europe Clinical Immunoanalyzer Market
      • 7.3.11.1. Market Size and Forecast, By Type
      • 7.3.11.2. Market Size and Forecast, By Application
      • 7.3.11.3. Market Size and Forecast, By End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Type
    • 7.4.3. Market Size and Forecast, By Application
    • 7.4.4. Market Size and Forecast, By End User
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. China Clinical Immunoanalyzer Market
      • 7.4.6.1. Market Size and Forecast, By Type
      • 7.4.6.2. Market Size and Forecast, By Application
      • 7.4.6.3. Market Size and Forecast, By End User
    • 7.4.7. Japan Clinical Immunoanalyzer Market
      • 7.4.7.1. Market Size and Forecast, By Type
      • 7.4.7.2. Market Size and Forecast, By Application
      • 7.4.7.3. Market Size and Forecast, By End User
    • 7.4.8. India Clinical Immunoanalyzer Market
      • 7.4.8.1. Market Size and Forecast, By Type
      • 7.4.8.2. Market Size and Forecast, By Application
      • 7.4.8.3. Market Size and Forecast, By End User
    • 7.4.9. South Korea Clinical Immunoanalyzer Market
      • 7.4.9.1. Market Size and Forecast, By Type
      • 7.4.9.2. Market Size and Forecast, By Application
      • 7.4.9.3. Market Size and Forecast, By End User
    • 7.4.10. Australia Clinical Immunoanalyzer Market
      • 7.4.10.1. Market Size and Forecast, By Type
      • 7.4.10.2. Market Size and Forecast, By Application
      • 7.4.10.3. Market Size and Forecast, By End User
    • 7.4.11. Rest of Asia-Pacific Clinical Immunoanalyzer Market
      • 7.4.11.1. Market Size and Forecast, By Type
      • 7.4.11.2. Market Size and Forecast, By Application
      • 7.4.11.3. Market Size and Forecast, By End User
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Type
    • 7.5.3. Market Size and Forecast, By Application
    • 7.5.4. Market Size and Forecast, By End User
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Clinical Immunoanalyzer Market
      • 7.5.6.1. Market Size and Forecast, By Type
      • 7.5.6.2. Market Size and Forecast, By Application
      • 7.5.6.3. Market Size and Forecast, By End User
    • 7.5.7. South Africa Clinical Immunoanalyzer Market
      • 7.5.7.1. Market Size and Forecast, By Type
      • 7.5.7.2. Market Size and Forecast, By Application
      • 7.5.7.3. Market Size and Forecast, By End User
    • 7.5.8. Saudi Arabia Clinical Immunoanalyzer Market
      • 7.5.8.1. Market Size and Forecast, By Type
      • 7.5.8.2. Market Size and Forecast, By Application
      • 7.5.8.3. Market Size and Forecast, By End User
    • 7.5.9. Rest of LAMEA Clinical Immunoanalyzer Market
      • 7.5.9.1. Market Size and Forecast, By Type
      • 7.5.9.2. Market Size and Forecast, By Application
      • 7.5.9.3. Market Size and Forecast, By End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Roche Diagnostics Corporation
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Abbott
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Siemens AG.
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Beckman Coulter
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. Ortho-Clinical Diagnostics
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Bio-Rad
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. BioMerieux
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. DiaSorin S.p.A.
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Werfen Life
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Thermo Fisher Scientific
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments